A new medication, Taltz, improves skin health in those with moderate-to-severe psoriasis.
A new drug that has shown “unprecedented” effects on the skin condition psoriasis seems to work well in the longer term, too, researchers report.
The drug, called ixekizumab (Taltz), was approved in March by the U.S. Food and Drug Administration. That came after initial trials showed that over 12 weeks, the drug soundly beat standard medication for moderate-to-severe psoriasis.
The new findings show the benefits are still there after 60 weeks. At that point, about 80 percent of patients were seeing at least a 75 percent improvement in their skin symptoms, the researchers said.
So far, ixekizumab has shown “unprecedented efficacy” against more severe cases of psoriasis, said Dr. Joel Gelfand, a dermatologist who wasn’t involved in the research.
The drug, given by injection, targets an inflammatory protein called IL-17, said Gelfand, who directs the Psoriasis and Phototherapy Treatment Center at the University of Pennsylvania.
The FDA approved another IL-17 inhibitor, called Cosentyx, last year.
“Targeting the IL-17 pathway has proven to be yet another revolution in our ability to treat psoriasis,” Gelfand said.
That said, he added, researchers need to keep tracking the drugs’ long-term effects.
Read Full Article: New Psoriasis Drug Works Longer Term, Too
|Read Full Article: New Psoriasis Drug Works Longer Term, Too|